Advance research projects from Lead Optimization through Candidate Selection stages through effective leadership of matrixed, multi-disciplinary teams with membership from discovery, precision medicine, preclinical safety and safety pharmacology, DMPK-BA, CMC, clinical development, and others.

Head of Cellular and Molecular Pharm group. Responsible for in vitro pharmacology for Immunology TA: target strategy, validation, and screening. Development & execution of biochemical, GPCR, nuclear receptor, cellular, phenotypic, target engagement, & MOA assays.Discovery project leadership: target validation, assay development, disease-relevant models, portfolio fitLicensing due diligenceNovel therapeutic modalitiesLeader/Co-leader, global Bio-Assay Leadership Team. Established best practices and enhanced infrastructure for plate-based assays & compound management across all AbbVie sites Lean Six Sigma Greenbelt certification

Abbott Bioresearch Ctr. through 2012Head of Enzymology Group, responsible for methods development, data generation, and MOA studies.

Led GPCR lab: potency, selectivity, and MOA assays to support multiple projects to selection of GLP tox candidates

Bench enzymologist supporting multiple kinase projectsLead for kinase biomarker platform Learned and established GPCR technology platform in ImmunologyProtein purification and characterization in support of enzymology, crystallography, and biologics

Bench enzymologist, responsible for assay development, compound evaluation, and HTS triage. Supported oncology kinase projects to selection of multiple candidates, including ABT-869/Linifanib

Studied the mechanism of the oncology target protein farnesyltransferaseTrained in molecular biology, synthetic chemistry, and bio-organic chemistryC. Dale Poulter, advisor, National Academy of Sciences

Studied the mechanism of D-amino acid oxidase using mutagenesis and pre-steady-state kineticsMirella Simonetta-Pilone, advisor